Prostatype Genomics (Sweden) Top Management

Prostatype Genomics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3871) % which means that it has lost $0.3871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7024) %, meaning that it generated substantial loss on money invested by shareholders. Prostatype Genomics' management efficiency ratios could be used to measure how well Prostatype Genomics manages its routine affairs as well as how well it operates its assets and liabilities. Prostatype Genomics owns a total of 22.86 Million outstanding shares. Roughly 85.53 pct. of Prostatype Genomics outstanding shares are held by general public with 1.0 % owned by insiders and only 13.47 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Prostatype Genomics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Prostatype Genomics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Prostatype Genomics Workforce Comparison

Prostatype Genomics Benchmark Summation

Prostatype Genomics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Prostatype Genomics often depends on how effective the management is. Prostatype Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prostatype management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prostatype management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Prostatype Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prostatype Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prostatype Genomics' management manipulating its earnings.

When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.